达雷妥尤单抗快速输注在多发性骨髓瘤患者中的长期安全性
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients.
作者信息
Gozzetti Alessandro, Bacchiarri Francesca, Sammartano Vincenzo, Defina Marzia, Sicuranza Anna, Mecacci Bianca, Zappone Elisabetta, Cencini Emanuele, Fabbri Alberto, Raspadori Donatella, Bocchia Monica
机构信息
Hematology Unit, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena, Italy.
出版信息
Front Oncol. 2020 Dec 21;10:570187. doi: 10.3389/fonc.2020.570187. eCollection 2020.
Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy also as a first treatment. However, to avoid the incidence of infusion reactions, long infusion schedules of 8 h at first dose and 4 h in the following doses are required, which can reduce the compliance of patients and health care professionals. A reduced infusion time of 90 min has been reported previously, but data are missing on the prolonged safety of this over time as well as the efficacy of this approach. In this work, we investigate the safety of 484 rapid Daratumumab infusions given early after the second dose over a 22 months period in 39 myeloma patients.
近年来，由于有了可用于治疗的新型药物，多发性骨髓瘤患者的生存率有了显著提高。抗CD38单克隆抗体达雷妥尤单抗对复发/难治性疾病患者特别有效，许多研究也表明其作为一线治疗同样具有前所未有的疗效。然而，为避免发生输注反应，首次给药需要8小时的长时间输注方案，后续剂量为4小时，这可能会降低患者和医护人员的依从性。此前曾报道过输注时间可缩短至90分钟，但随着时间推移这种方法的长期安全性以及疗效方面的数据尚缺。在这项研究中，我们调查了39例骨髓瘤患者在22个月内于第二次给药后早期进行484次达雷妥尤单抗快速输注的安全性。
Zotero 插件